# A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

> **NCT02254538** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BILR 355 BS
- **DRUG:** PEG 400

## Key facts

- **NCT ID:** NCT02254538
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-02
- **Final completion:** —
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254538, "A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02254538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*